TAK ▲ +0.1% - Takeda Pharmaceutical Company Limited $TAK Takeda: Phase 3 Gastric Cancer Trial Meets Both Primary Endpoints, Reducing Risk of Death by 43% ? • Overall Survival: Median 10.2 months vs. 6.9 months with standard treatment (HR 0.57, p<escape><</escape>0.0001). • Progression-Free Survival: 7.1 months vs. 3.1 months (HR 0.45), with response rates of 37.4% vs. 7.7%. • Next Steps: Takeda plans a regulatory filing in Japan and additional global Phase 3 trials in gastric and pancreatic cancer. 23-OCT-2026 07:34 AM ET